Is rosuvastatin protective against sepsis-associated encephalopathy? A secondary analysis of the SAILS trial.

Autor:	Yu SY; Emergency Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China., Ge ZZ; Emergency Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China., Xiang J; General Medicine Department of Jingnan Medical Center, General Hospital of PLA, Beijing 100039, China., Gao YX; Emergency Department, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China., Lu X; Emergency Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China., Walline JH; Department of Emergency Medicine, Penn State Health, Milton S. Hershey Medical Center, Hershey 17033, USA., Qin MB; Emergency Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China., Zhu HD; Emergency Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China., Li Y; Emergency Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China.
Jazyk:	angličtina
Zdroj:	World journal of emergency medicine [World J Emerg Med] 2022; Vol. 13 (5), pp. 367-372.
DOI:	10.5847/wjem.j.1920-8642.2022.072
Abstrakt:	Background: Sepsis is a common cause of death in emergency departments and sepsis-associated encephalopathy (SAE) is a major complication. Rosuvastatin may play a neuroprotective role due to its protective effects on the vascular endothelium and its anti-inflammatory functions. Our study aimed to explore the potential protective function of rosuvastatin against SAE. Methods: Sepsis patients without any neurological dysfunction on admission were prospectively enrolled in the "Rosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome" study (SAILS trial, ClinicalTrials.gov number: NCT00979121). Patients were divided into rosuvastatin and placebo groups. This is a secondary analysis of the SAILS dataset. Baseline characteristics, therapy outcomes, and adverse drug events were compared between groups. Results: A total of 86 patients were eligible for our study. Of these patients, 51 were treated with rosuvastatin. There were significantly fewer cases of SAE in the rosuvastatin group than in the placebo group (32.1% vs. 57.1%, P=0.028). However, creatine kinase levels were significantly higher in the rosuvastatin group than in the placebo group (233 [22-689] U/L vs. 79 [12-206] U/L, P=0.034). Conclusion: Rosuvastatin appears to have a protective role against SAE but may result in a higher incidence of adverse events. Competing Interests: Conflicts of interest: The authors declare that they have no competing interests. (Copyright: © World Journal of Emergency Medicine.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF